



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

MAY 17 2007

Re: X-Stop Interspinous Process  
Decompression System  
Docket No.: 2006E-0259

The Honorable Jon Dudas  
Undersecretary of Commerce for Intellectual Property  
Director of the United States Patent and Trademark Office  
Mail Stop Hatch-Waxman PTE  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 6,235,030, filed by St. Francis Medical Technologies, Inc., under 35 U.S.C. § 156 *et seq.* We have reviewed the dates contained in the application and have determined the regulatory review period for X-Stop Interspinous Process Decompression System, the medical device claimed by the patent.

The total length of the regulatory review period for X-Stop Interspinous Process Decompression System is 2,224 days. Of this time, 1,538 days occurred during the testing phase and 686 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under section 520(g) of the Federal Food, Drug, and Cosmetic Act involving this device became effective: October 22, 1999.

The applicant claims that the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act for human tests to begin became effective on February 11, 2000. However, FDA records indicate that the IDE was determined substantially complete for clinical studies to have begun on October 22, 1999, which represents the IDE effective date.

2. The date the application was initially submitted with respect to the device under section 515 of the Federal Food, Drug, and Cosmetic Act: January 6, 2004.

FDA has verified the applicant's claim that the premarket approval application (PMA) for X-Stop Interspinous Process Decompression System (PMA P040001) was initially submitted on January 6, 2004.

3. The date the application was approved: November 21, 2005.

FDA has verified the applicant's claim that PMA P040001 was approved on November 21, 2005.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,



Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

cc: Sheldon R. Meyer  
Fliesler Meyer LLP  
Customer # 23910  
Four Embarcadero Center, 4th Floor  
San Francisco, CA 94111-4156